Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy121% reduction ...

Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems.

Governor Josh Stein announced Monday that Genentech, one of the world’s premiere biotechnology companies, will invest $700 ...

Genentech plans to invest $700 million in a new facility in Holly Springs, North Carolina, creating 420 jobs and joining the ...

The U.S. secured over $1 billion in new manufacturing investment today on the back of President Trump’s push for more domestic production. Receive undervalued stocks, resilient to market uncertainty, ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

Genentech, a Bay Area-based biotech firm and member of the Switzerland-based Roche Group, plans to develop a $700 million pharmaceutical manufacturing facility in Holly Springs, approximately 20 miles ...

The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.